Does interval between screening and baseline matter in HD cognitive clinical trials?

Leigh J Beglinger; William H Adams; Douglas Langbehn; Jess G Fiedorowicz; John Caviness; Kevin Biglan; Blair Olson; Jane S Paulsen

doi:10.3233/JHD-140100

Back

Does interval between screening and baseline matter in HD cognitive clinical trials?

Journal article

Peer reviewed

Does interval between screening and baseline matter in HD cognitive clinical trials?

Leigh J Beglinger, William H Adams, Douglas Langbehn, Jess G Fiedorowicz, John Caviness, Kevin Biglan, Blair Olson and Jane S Paulsen

Journal of Huntington's disease, Vol.3(2), pp.139-144

2014

DOI: 10.3233/JHD-140100

PMID: 25062857

View Online

Abstract

"Practice effects" (PE), or performance improvements due to prior exposure to testing, are known to confound cognitive test results, particularly when short intervals occur between two test sessions. We examined two subsamples with short or long re-test intervals from a recent clinical trial. Thirty-four non-depressed adults with mild Huntington Disease (HD) participated. Three cognitive tests were administered at screening and again at baseline, before active treatment randomization. Half the sample had a 24-hour retest interval while the other half was >6-days. The two groups differed on demographic/clinical factors (age, Total Motor Score and Total Functional Capacity). After controlling for age and motor score, PE differences were found on three of the five UHDRS cognitive tests: the longer interval group showed larger PE on Symbol-Digit Modalities and Stroop color, while the rapid interval group had larger PE on Stroop interference. Controlling for screening cognitive performance yielded similar results. Length of interval between screening and baseline visits and level of disease severity may influence stability of UHDRS cognitive test results in clinical trials in HD.

Severity of Illness Index

Dementia - psychology

Humans

Middle Aged

Huntington Disease - psychology

Dementia - diagnosis

Male

Cognition - drug effects

Disease Progression

Huntington Disease - complications

Neuropsychological Tests

Cognition Disorders - diagnosis

Dementia - etiology

Time Factors

Cognition Disorders - etiology

Adult

Female

Huntington Disease - drug therapy

Cognition Disorders - psychology

Details

Title: Subtitle: Does interval between screening and baseline matter in HD cognitive clinical trials?
Creators: Leigh J Beglinger - University of Iowa, Iowa City, IA, USA Elks Rehab Hospital, Boise, ID, USA
William H Adams - Loyola University Chicago, Chicago, IL, USA
Douglas Langbehn - University of Iowa, Iowa City, IA, USA
Jess G Fiedorowicz - University of Iowa, Iowa City, IA, USA
John Caviness - Mayo Clinic Scottsdale, Scottsdale, AZ, USA
Kevin Biglan - University of Rochester, Rochester, NY, USA
Blair Olson - University of Iowa, Iowa City, IA, USA
Jane S Paulsen - University of Iowa, Iowa City, IA, USA
Resource Type: Journal article
Publication Details: Journal of Huntington's disease, Vol.3(2), pp.139-144
DOI: 10.3233/JHD-140100
PMID: 25062857
NLM abbreviation: J Huntingtons Dis
ISSN: 1879-6397
eISSN: 1879-6400
Publisher: Netherlands
Grant note: NS055733-01 / NINDS NIH HHS
Language: English
Date published: 2014
Academic Unit: Psychiatry; Epidemiology; Psychological and Brain Sciences; Iowa Neuroscience Institute; Internal Medicine
Record Identifier: 9984003966502771

Metrics

27 Record Views

2 Times Cited - Web of Science